Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Avian Influenza Vaccine, H5N2 Subtype, Killed Virus
- Development stage
- Unknown
- Lead developer
- Zoetis
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
A veterinary vaccine indicated for the immunization of healthy chickens (3 weeks of age or older) against disease caused by highly pathogenic avian influenza (HPAI) viruses of the H5 subtype. This inactivated (killed virus) vaccine contains avian influenza virus isolates rgH5N2—specifically A/turkey/Indiana/22-003707-003/2022 H5; A/chicken/Egypt/D5490B/2012 N2; and a PR8 backbone. The product is administered as a single 0.5 mL subcutaneous dose and is conditionally licensed by the USDA based on demonstration of safety, purity, and reasonable expectation of efficacy from serology data. It is used exclusively under official animal disease control programs in the United States to help protect poultry flocks from circulating strains of highly pathogenic avian influenza[1][2][3][6]. The N2 designation helps differentiate vaccinated birds from naturally infected ones[5]. Developed and manufactured by Zoetis.
- Other names
- Avian Influenza Vaccine H5N2 Subtype Killed VirusH5N2 killed virus vaccineH-5N2 killed virus vaccineH 5N2 killed virus vaccine
02
Targets
NeuraminidaseHA (Hemagglutinin)
Beyond the preview
Go deeper on Avian Influenza Vaccine, H5N2 Subtype, Killed Virus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avian Influenza Vaccine, H5N2 Subtype, Killed Virus.